Johnson & Johnson and Bayer Pharmaceuticals are facing a new Xarelto lawsuit from a collective group of plaintiffs alleging dangerous and deadly Xarelto side effects.

Each of these claimants allege that they or one of their loved ones suffered uncontrollable internal bleeding injuries as a result of Xarelto side effects.

One of the claimants named in this Xarelto lawsuit is Maryland plaintiff Quonchita J., who is filing legal action on behalf of Joann B.

Joann had been prescribed Xarelto from January 2011 to May 2013, but had stopped using the drug after suffering alleged Xarelto side effects. However, the internal bleeding injuries were too severe and resulted in Joann’s death.

Xarelto is a new generation anticoagulant, which is popularly prescribed to patients who are at high risk for stroke or suffering atrial fibrillation.

Unlike its predecessor Warfarin, Xarelto has no reversal agent in the case of internal bleeding with no mention of the risk on the drug’s warning label.

Even though this drug has become the second most popular anticoagulant on the market, scientists point out that the clotting inhibition of Xarelto allows for the possibility of uncontrolled internal bleeding.

This was the case of Joann, who died from her Xarelto side effects after suffering an internal bleeding hemorrhage.

As the executor of Joann’s estate, Quonchita is joining the Xarelto lawsuit alleging wrongful death and other serious charges.

Like the other claimants in the Xarelto lawsuit, Quonchita states that Joann never would have used Xarelto if she knew the risk of internal bleeding.

Overview of Xarelto Side Effects

Xarelto was approved by the FDA in 2011, and was released as a joint venture between Bayer Pharmaceuticals and Johnson & Johnson.

Its release came only a year after Pradaxa, which was the first drug to break through into the anticoagulant since Warfarin’s release in the 1960s.

However, it was not long after its release that patients started reporting adverse Xarelto side effects.

Bayer and Johnson & Johns had reportedly spent at least $11 million on advertising Xarelto along in 2013, to insure that patients and doctors heard of the drug’s side effects.

The aggressive advertising campaign worked, earning $582 million in worldwide sales in its first year of sale.

However, critics state that the companies exaggerated the drug’s benefits, and did not adequately describe the risks. In result, patients suffered numerous internal bleeding injuries with some resulting in deaths.

This has resulted in numerous Xarelto lawsuits being filed against Bayer and Johnson & Johnson. Quonchita’s is one of these lawsuits, joining a multidistrict litigation (MDL) consisting of similar claimants.

This Xarelto Lawsuit is filed with the larger Xarelto multidistrict litigation, MDL No. 2592, in the U.S. District Court of Eastern Louisiana.